Laughter Frequency and Fibromyalgia Symptoms (LAF)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02957110|
Recruitment Status : Completed
First Posted : November 6, 2016
Last Update Posted : May 7, 2018
|Condition or disease||Intervention/treatment|
|Fibromyalgia||Behavioral: Laughter Frequency|
Participants will be asked to provide (or authorize the researcher to obtain) fibromyalgia diagnosis confirmation from a health care provider.
Initially, participants will complete a demographics form and two screening assessments. Then for 14 days, they will be asked to rate their momentary mood and overall pain levels three times per day (shortly after waking up, around 3:00 p.m., and at about an hour before bedtime). At the same time, they will be asked to log each instance of laughter as it occurs, daily, for 14 days. They will carry the log with them throughout each day in order to document each instance of laughter.
|Study Type :||Observational|
|Actual Enrollment :||41 participants|
|Official Title:||The Relationships Between Laughter Frequency, Pain Perception, and Affect in Fibromyalgia Patients|
|Study Start Date :||November 2016|
|Actual Primary Completion Date :||October 2017|
|Actual Study Completion Date :||October 2017|
- Behavioral: Laughter Frequency
Relationships between laughter frequency, momentary mood state, and pain will be observed.
- Laughter Frequency [ Time Frame: 14 days ]Documenting each instance of laughter throughout each day.
- Pain Ratings [ Time Frame: Three times per day for 14 days ]Rating overall pain from 0 to 10, three times daily
- Emotional State [ Time Frame: Three times per day for 14 days ]Rating momentary emotional state three times per day
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02957110
|United States, Minnesota|
|Minneapolis, Minnesota, United States, 55401|
|Study Chair:||Ellen Levine, PhD||Walden University|